Researchers are testing whether the Clarity ctDNA test can reliably identify patients who do just as well long term with less chemotherapy.

The "Genomic Reference Materials and Controls Systems Market: Focus on Product Type, Application, End User, and Country-Level Analysis - Analysis and Forecast, 2025-2035" report has been added to ...

Foresight Diagnostics Inc., a Boulder-based cancer diagnostics company that specialized in the development of ultra-sensitive minimal residual disease, or MRD, detection, recently expanded its ...

Patients who received cilta-cel had improvements in progression-free survival and overall survival if they had sustained a minimal residual disease-negative complete response or better for at least 1 ...

Personalis, Inc. (Nasdaq: PSNL), in collaboration with Professor Nick Turner, Dr. Isaac Garcia-Murillas and their colleagues at The Institute of Cance ...

Revuforj® (revumenib) net product revenue in initial five weeks of launch – – Launched Niktimvo™ (axatilimab-csfr) in the U.S. in late January, in partnership with Incyte – – sNDA filing for revumenib ...

Discover how ctDNA revolutionizes multiple myeloma monitoring, tracking disease progression, and improving personalized ...

In this video, Arvind Dasari, MD, MS, discussed data from multiple ASCO Gastrointestinal Cancers Symposium presentations highlighting the use of ctDNA as a minimal residual disease in colorectal ...

Dr. Christopher R. Flowers explains that MRD testing varies by cancer type, with results impacting recurrence risk and ...

Allogene Therapeutics (ALLO) announced an expanded strategic collaboration with Foresight Diagnostics to include the development of Foresight’s ...

The test has met coverage requirements for use with patients with non-small cell lung cancer with resectable or unresectable disease in the surveillance setting.

Despite a solid long-term growth story and strong cash reserves, the high VCYT stock valuation suggests a "hold" rating until ...